Because gliosis contributes to obesity pathogenesis [36, 37], it is not surprising that this beneficial effect of NLRP3 inhibition augments the efficacy of GLP‐1RAs, especially because gliosis does not appear to be a key target for the action of the latter drug class. The gene discussed is NLRP3; the disease is obesity due to melanocortin 4 receptor deficiency.